Most Popular
-
1
[Exclusive] Korean military set to ban iPhones over 'security' concerns
![[Exclusive] Korean military set to ban iPhones over 'security' concerns](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050599_0.jpg&u=20240423183955)
-
2
Korean, Romanian leaders discuss defense tech, nuclear energy
-
3
[Graphic News] 77% of young Koreans still financially dependent
![[Graphic News] 77% of young Koreans still financially dependent](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/22/20240422050762_0.gif&u=)
-
4
S. Korea calls on Japan to confront history amid Yasukuni Shrine visit
-
5
Yoon’s jailed mother-in-law excluded from latest parole list
![[Exclusive] Korean military set to ban iPhones over 'security' concerns](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050599_0.jpg&u=20240423183955)
![[Graphic News] 77% of young Koreans still financially dependent](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/22/20240422050762_0.gif&u=)
-
6
Hybe and Min Hee-jin, CEO of Hybe sublabel Ador, lock horns
-
7
[Pressure points] Leggings in public: Fashion statement or social faux pas?
![[Pressure points] Leggings in public: Fashion statement or social faux pas?](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050669_0.jpg&u=)
-
8
North Korea fires several short-range ballistic missiles into sea: JCS
-
9
Samsung, SK hynix investors dump shares on Nvidia crash
-
10
Yoo Jae-suk, Yoo Yeon-seok team up in 'Whenever Possible'
![[Pressure points] Leggings in public: Fashion statement or social faux pas?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050669_0.jpg&u=)
Lotte taps former Samsung Biologics exec to lead bio business
By Kan Hyeong-wooPublished : June 10, 2022 - 15:05
Lotte Biologics has picked Lee Won-jik, a former Samsung Biologics executive, to lead its bio business as the company’s CEO.
Born in 1977, Lee has over two decades of experience in global biologics and the pharmaceuticals industry, including working at the US Department of Health and Human Services and Bristol Myers Squibb. Before he joined Lotte in August, Lee was the head of Samsung Biologics’ drug product business unit.
Lotte Biologics and its new CEO will officially debut at the upcoming Bio International Convention, which is slated to begin Monday in San Diego, according to a Lotte Holdings official.
Lotte Holdings on Thursday announced in a public notice that it has completed the registration of Lotte Biologics’ incorporation with a starting capital of 1 billion won ($790,000).
Last month, Lotte Group said it will invest 2.5 trillion won into expanding its bio businesses over the next 10 years with the goal of becoming among the top 10 largest contract manufacturing and development organizations in the world by 2030.
Lotte acquired Bristol Myers Squibb’s manufacturing facility in East Syracuse, New York, for $160 million, signaling the beginning of the group’s initiatives to enter the bio industry.
Born in 1977, Lee has over two decades of experience in global biologics and the pharmaceuticals industry, including working at the US Department of Health and Human Services and Bristol Myers Squibb. Before he joined Lotte in August, Lee was the head of Samsung Biologics’ drug product business unit.
Lotte Biologics and its new CEO will officially debut at the upcoming Bio International Convention, which is slated to begin Monday in San Diego, according to a Lotte Holdings official.
Lotte Holdings on Thursday announced in a public notice that it has completed the registration of Lotte Biologics’ incorporation with a starting capital of 1 billion won ($790,000).
Last month, Lotte Group said it will invest 2.5 trillion won into expanding its bio businesses over the next 10 years with the goal of becoming among the top 10 largest contract manufacturing and development organizations in the world by 2030.
Lotte acquired Bristol Myers Squibb’s manufacturing facility in East Syracuse, New York, for $160 million, signaling the beginning of the group’s initiatives to enter the bio industry.
